What's Happening?
In a recent episode of the podcast 'Denatured,' experts Dr. Jihye Jang-Lee and Dr. Khanh Courtney discuss how the healthcare and pharmaceutical sectors are adapting to global supply chain disruptions.
The conversation, hosted by Jennifer Smith-Parker and Lori Ellis from BioSpace, explores the shift from cost control to capability building. The focus is on creating a more resilient and agile ecosystem, particularly in response to U.S. tariffs. The discussion highlights the need for local grounding and strategic adjustments to ensure continuity and efficiency in pharmaceutical operations.
Why It's Important?
The pharmaceutical industry's strategic shift is crucial in maintaining the supply of essential medicines and healthcare products amid global disruptions. This transformation is likely to impact various stakeholders, including manufacturers, healthcare providers, and patients. By building local capabilities and enhancing supply chain resilience, the industry can better withstand future challenges, ensuring that critical healthcare needs are met. This approach also aligns with broader economic and policy trends emphasizing domestic production and reduced dependency on international supply chains.
